MediciNova reports additional Phase II data for ibudilast in ALS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported data from 51 evaluable amyotrophic lateral sclerosis (ALS) patients without non-invasive ventilation in a Phase II trial showing that once-daily 60 mg oral

Read the full 286 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE